EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
- Rosenberg, J.E.
- Powles, T.
- Sonpavde, G.P.
- Loriot, Y.
- Duran, I.
- Lee, J.-L.
- Matsubara, N.
- Vulsteke, C.
- Castellano, D.
- Mamtani, R.
- Wu, C.
- Matsangou, M.
- Campbell, M.
- Petrylak, D.P.
Revista:
Annals of Oncology
ISSN: 1569-8041, 0923-7534
Año de publicación: 2023
Tipo: Artículo